AU2016327930B2 - Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof - Google Patents

Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof Download PDF

Info

Publication number
AU2016327930B2
AU2016327930B2 AU2016327930A AU2016327930A AU2016327930B2 AU 2016327930 B2 AU2016327930 B2 AU 2016327930B2 AU 2016327930 A AU2016327930 A AU 2016327930A AU 2016327930 A AU2016327930 A AU 2016327930A AU 2016327930 B2 AU2016327930 B2 AU 2016327930B2
Authority
AU
Australia
Prior art keywords
group
liver
mannitol
compound
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016327930A
Other languages
English (en)
Other versions
AU2016327930A1 (en
Inventor
Hsin-Tien HO
Cheng-Huei Hsiong
Oliver Yoa-Pu Hu
Tung-Yuan SHIH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sinew Pharma Inc
Original Assignee
Sinew Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2016/078039 external-priority patent/WO2017084234A1/zh
Application filed by Sinew Pharma Inc filed Critical Sinew Pharma Inc
Publication of AU2016327930A1 publication Critical patent/AU2016327930A1/en
Application granted granted Critical
Publication of AU2016327930B2 publication Critical patent/AU2016327930B2/en
Priority to AU2021205040A priority Critical patent/AU2021205040B2/en
Priority to AU2024200963A priority patent/AU2024200963A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/16—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation
    • C07C51/21—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with molecular oxygen
    • C07C51/215—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with molecular oxygen of saturated hydrocarbyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/42—Glutaric acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2016327930A 2015-09-24 2016-09-26 Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof Active AU2016327930B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021205040A AU2021205040B2 (en) 2015-09-24 2021-07-14 Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
AU2024200963A AU2024200963A1 (en) 2015-09-24 2024-02-14 Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562222959P 2015-09-24 2015-09-24
US62/222,959 2015-09-24
US201562257697P 2015-11-19 2015-11-19
US62/257,697 2015-11-19
AUPCT/CN2016/078039 2016-03-31
PCT/CN2016/078039 WO2017084234A1 (zh) 2015-11-19 2016-03-31 预防或治疗脂肪肝的药物组合物
PCT/CN2016/100187 WO2017050298A1 (en) 2015-09-24 2016-09-26 Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021205040A Division AU2021205040B2 (en) 2015-09-24 2021-07-14 Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof

Publications (2)

Publication Number Publication Date
AU2016327930A1 AU2016327930A1 (en) 2018-05-10
AU2016327930B2 true AU2016327930B2 (en) 2021-04-15

Family

ID=60047309

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016327930A Active AU2016327930B2 (en) 2015-09-24 2016-09-26 Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
AU2021205040A Active AU2021205040B2 (en) 2015-09-24 2021-07-14 Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
AU2024200963A Pending AU2024200963A1 (en) 2015-09-24 2024-02-14 Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021205040A Active AU2021205040B2 (en) 2015-09-24 2021-07-14 Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
AU2024200963A Pending AU2024200963A1 (en) 2015-09-24 2024-02-14 Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof

Country Status (20)

Country Link
US (4) US10456371B2 (cg-RX-API-DMAC7.html)
EP (3) EP4609911A3 (cg-RX-API-DMAC7.html)
JP (2) JP2018537517A (cg-RX-API-DMAC7.html)
KR (2) KR102891137B1 (cg-RX-API-DMAC7.html)
CN (3) CN120398980A (cg-RX-API-DMAC7.html)
AU (3) AU2016327930B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018005905B1 (cg-RX-API-DMAC7.html)
CA (2) CA3232521A1 (cg-RX-API-DMAC7.html)
EA (1) EA201890810A1 (cg-RX-API-DMAC7.html)
ES (1) ES3044383T3 (cg-RX-API-DMAC7.html)
HK (1) HK1244266A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20250899T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072982T2 (cg-RX-API-DMAC7.html)
MX (2) MX395231B (cg-RX-API-DMAC7.html)
MY (1) MY190647A (cg-RX-API-DMAC7.html)
PH (1) PH12018500659A1 (cg-RX-API-DMAC7.html)
SG (1) SG10202002573RA (cg-RX-API-DMAC7.html)
TW (1) TWI781912B (cg-RX-API-DMAC7.html)
WO (1) WO2017050298A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201802373B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015070396A1 (zh) * 2013-11-13 2015-05-21 财团法人国防教育研究基金会 无肝副作用的对乙酰胺基酚新复方组合
EA201890810A1 (ru) 2015-09-24 2018-11-30 Синью Фарма Инк. Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
CN107613968A (zh) * 2015-11-19 2018-01-19 欣耀生医股份有限公司 预防或治疗脂肪肝的药物组合物
US20210008101A1 (en) * 2018-02-14 2021-01-14 Sinew Pharma Inc. Methods and compositions for preventing, reducing or eradicating toxicity caused by acetaminophen (apap)
CN110538187A (zh) * 2018-05-28 2019-12-06 北京大学 Cpt1激活剂
KR102136326B1 (ko) * 2018-09-06 2020-07-22 서울대학교산학협력단 가시박으로부터 분리한 플라보노이드 유도체를 유효성분으로 포함하는 간 질환 예방 또는 치료용 조성물
TWI691719B (zh) * 2018-10-19 2020-04-21 香港商阿瓦隆 海帕波有限公司 半乳糖快速定量檢測系統及其應用
CN109920550A (zh) * 2018-12-25 2019-06-21 天津大学 一种基于dMRI研究青少年肌阵挛性癫痫的方法
KR20210138579A (ko) * 2019-01-21 2021-11-19 싱가포르 헬스 서비시즈 피티이 엘티디 간독성의 치료
CN110269855A (zh) * 2019-07-19 2019-09-24 辽宁大学 黄酮类小分子化合物在制备抑制胰脂肪酶活性药物中的应用
US12383191B1 (en) * 2020-05-04 2025-08-12 PathAI, Inc. Systems and methods for assessing liver pathology
CN113999272A (zh) * 2021-10-29 2022-02-01 广西医科大学 香蜂草苷的制备方法及其应用
CN113875982A (zh) * 2021-11-19 2022-01-04 武汉森澜生物科技有限公司 一种含二氢杨梅素的抗衰组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140141082A1 (en) * 2012-11-16 2014-05-22 Song Gao Compositions Containing Enriched Natural Crocin and/or Crocetin, and Their Therapeutic or Nutraceutical Uses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661519A (en) * 1983-04-12 1987-04-28 Pola Chemical Industries Inc. Method for dermatological application
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
JP3916685B2 (ja) * 1996-02-29 2007-05-16 第一製薬株式会社 ガラクトース誘導体
JP4677550B2 (ja) * 2002-08-14 2011-04-27 独立行政法人産業技術総合研究所 環状エステル化合物
TWI287990B (en) * 2004-01-08 2007-10-11 Nat Defense Medical Ct Inhibitors and enhancers of uridine diphosphate-glucuronosyl transferase 2B (UGT2B)
WO2006010083A2 (en) * 2004-07-08 2006-01-26 Molecular Therapeutics, Inc. Biodegradable nanoparticles
CN1939929A (zh) * 2005-09-29 2007-04-04 云南白药集团股份有限公司 一种偏诺皂苷类化合物酸式盐及制备方法
US8969312B2 (en) * 2011-04-20 2015-03-03 National Defense Education And Research Foundation Low side effect pharmaceutical composition containing antituberculosis drugs
KR20150084897A (ko) * 2012-11-12 2015-07-22 세게티스, 인코포레이티드. 가교성 폴리케탈 에스터, 그의 제조 방법 및 용도
MX2015014956A (es) * 2013-04-29 2016-08-08 Chigurupati Tech Private Ltd Toxicidad reducida en bebidas alcoholicas.
TWI552748B (zh) 2013-10-25 2016-10-11 The use of a compound for the removal of hepatotoxicity against Acetaminophen (APAP)
CN104623670A (zh) * 2013-11-06 2015-05-20 高松 一种含西红花素的组合物及其应用
WO2015070396A1 (zh) 2013-11-13 2015-05-21 财团法人国防教育研究基金会 无肝副作用的对乙酰胺基酚新复方组合
CN104292289B (zh) * 2014-07-10 2017-12-29 程怡 半乳糖配体及其在肝靶向脂质体中的应用
EA201890810A1 (ru) * 2015-09-24 2018-11-30 Синью Фарма Инк. Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
CN107613968A (zh) * 2015-11-19 2018-01-19 欣耀生医股份有限公司 预防或治疗脂肪肝的药物组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140141082A1 (en) * 2012-11-16 2014-05-22 Song Gao Compositions Containing Enriched Natural Crocin and/or Crocetin, and Their Therapeutic or Nutraceutical Uses

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Kandeel, E. M., et al, Journal of Dispersion Science and Technology, 2012, 33, 949-54 *
Kayano, S., et al, Phytochemistry, 2014, 8, 132-6 *
Lech, K., et al, Journal of Mass Spectrometry, 2009, 44, 1661-7 *
Mahcamov, R. R. et al, Uzbekskii Khimicheskii Zhurnal, 1992, vol. 3-4, 27-30 *
Pittenauer, E., et al, Journal of Mass Spectrometry, 2013, 48, 1299-307 *
Rohrdanz, D., et al, Deutsche Lebensmittel-Rundschau, 1983, 79, 285-289 *
Wu, W. -J., et al, Tetrahedron, 2014, 70, 92-6 *
Yang, W., et al, Proceedings of the National Academy of Sciences, 2010, 107(26), 12040-5 *

Also Published As

Publication number Publication date
MX395231B (es) 2025-03-25
TW201722897A (zh) 2017-07-01
US20220265587A1 (en) 2022-08-25
HK1244266A1 (zh) 2018-08-03
CN120398980A (zh) 2025-08-01
US20200009097A1 (en) 2020-01-09
KR20180058795A (ko) 2018-06-01
EP3991724A2 (en) 2022-05-04
TWI781912B (zh) 2022-11-01
AU2024200963A1 (en) 2024-03-07
KR102891137B1 (ko) 2025-11-25
CA2999368A1 (en) 2017-03-30
PH12018500659A1 (en) 2018-10-01
BR112018005905A2 (pt) 2018-10-16
EP3991724A3 (en) 2022-07-27
CN120349362A (zh) 2025-07-22
JP2018537517A (ja) 2018-12-20
ZA201802373B (en) 2019-04-24
HRP20250899T1 (hr) 2025-11-07
AU2016327930A1 (en) 2018-05-10
EP3353144A4 (en) 2019-06-05
ES3044383T3 (en) 2025-11-26
JP7261850B2 (ja) 2023-04-20
CA3232521A1 (en) 2017-03-30
CN107614475A (zh) 2018-01-19
EP4609911A3 (en) 2025-11-19
EP3991724B1 (en) 2025-07-16
US20240335404A1 (en) 2024-10-10
WO2017050298A1 (en) 2017-03-30
BR112018005905B1 (pt) 2023-03-21
AU2021205040A1 (en) 2021-08-12
EP3991724C0 (en) 2025-07-16
MX2018003700A (es) 2018-08-01
EP3353144A1 (en) 2018-08-01
KR20240042148A (ko) 2024-04-01
MY190647A (en) 2022-04-30
US20180256526A1 (en) 2018-09-13
SG10202002573RA (en) 2020-05-28
AU2021205040B2 (en) 2023-11-16
EP4609911A2 (en) 2025-09-03
US12083088B2 (en) 2024-09-10
JP2022009680A (ja) 2022-01-14
HUE072982T2 (hu) 2025-12-28
US10456371B2 (en) 2019-10-29
MX2022007816A (es) 2022-08-02
US11285123B2 (en) 2022-03-29
EA201890810A1 (ru) 2018-11-30

Similar Documents

Publication Publication Date Title
AU2021205040B2 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
Wang et al. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity
Nie et al. Discovery and anti-diabetic effects of novel isoxazole based flavonoid derivatives
He et al. Antifungal and wound healing promotive compounds from the resins of Dracaena cochinchinensis
JP2018184414A (ja) 新規フラボノイド化合物およびその使用
AU2006330114A1 (en) Benzopyranone derivatives and their use as anti-coronaviral agents
KR101356945B1 (ko) 세이마토스포리움 디스코시오이데스에서 분리된 신규 폴리하이드록실레이티드 마크로라이드 유도체 및 이의 용도
EA040650B1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
Chen et al. Aryltetralin Lignan Glycosides From the Leaves of Viburnum cylindricum and Their Enzyme Inhibitory Activity
Wang Improving sulforaphane bioavailability from cooked broccoli
Hmidene Study on Phytochemicals and Bioactivities of the Medicinal Halophyte Tamarix gallica
CN116747235A (zh) 7-o-(4-o-甲基葡萄糖)-芒柄花素在制备降尿酸药物中的用途
CN116102596A (zh) 灯盏乙素苷元7位磷酸酯类衍生物及其制备方法及用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)